Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkins lymphoma, non-small cell lung cancer and oesophageal cancer.
Purity:
98.5%
CAS Number:
[2072873-06-2]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
